Delivery of contrast agents for magnetic resonance imaging, computed tomography, nuclear medicine and ultrasound

Advanced Drug Delivery Reviews

Volumn 37, Issue 1-3, 1999, Pages 33-51

  Tilcock, Colin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Blood pool; Cardiac imaging; Computed tomography; CT; Imaging; Lipid vesicle; Liposome; Magnetic resonance; MR; Nuclear medicine; Polyethylene glycol; RES avoidance; Ultrasound

Indexed keywords

AGENTS; BLOOD; CARDIOLOGY; CELL MEMBRANES; COMPUTERIZED TOMOGRAPHY; LIPIDS; MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; POLYETHYLENE GLYCOLS; ULTRASONIC IMAGING;

BLOOD POOL; CARDIAC IMAGING; LIPID VESICLE; LIPOSOMES; SURFACE LABELING;

CONTROLLED DRUG DELIVERY;

CHELATE; CONTRAST MEDIUM; ECHO CONTRAST MEDIUM; GADOLINIUM PENTETATE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IMMUNOLIPOSOME; LIPOSOME; MACROGOL; NONOXINOL 9; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PENTETIC ACID; TECHNETIUM 99M;

COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ELECTRON SPIN RESONANCE; ENCAPSULATION; HUMAN; IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; THEORY; ULTRASOUND;

EID: 0345390161     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00109-4     Document Type: Review

References (121)

1. H. Gupta, R. Weissleder, Targeted contrast agents in MR imaging, Magn. Reson. Imag. Clin. N. Am. 4(1) (1996) 171-184.
2. V.P. Torchilin, Pharmacokinetic considerations in the development of labeled liposomes and micelles for diagnostic imaging, J. Nucl. Med. 41(2) (1997) 141-153.
3. G. Poste, R. Kirsh, T. Koestler, The challenge of liposome targeting in vivo, in: G. Gregoriadis (Ed.), Liposome Technology, vol. 3, CRC Press, Boca Raton, FL, 1984.
4. J.H. Senior, Fate and behavior of liposomes in vivo: a review of controlling factors, CRC Crit. Rev. Ther. Drug Carrier Syst. 3 (1987) 123-193.
5. W.T. Phillips, A.S. Rudolph, B. Goins, R. Klipper, Biodistribution studies of liposome encapsulated hemoglobin (LEH) studies with newly developed 99m-technetium liposome label, Biomater. Artif. Cells Immobil. Technol. 20 (1992) 757-760.
6. G. Storm, C. Ousseren, P.A.M. Peeter, Y. Barenholz, Tolerability of liposomes in vivo, in: G. Gregoriadis (Ed.), Liposome Technology, vol. 3, CRC Press, Boca Raton, FL, 1993, pp. 345-383.
7. A. Abuchowski, J.R. McCoy, N.S. Palczuk, T. van Es, F.F. Davis, The effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase, J. Biol. Chem. 252(11) (1977) 3582-3586.
8. L. Illum, S. Davis, The organ uptakeof intravenously administered colloidal particles can be altered by using nonionic surfactant (Poloxamer 338), FEBS Lett. 167(1) (1984) 79-82.
9. M.C. Woodle, D.D. Lasic, Sterically-stabilized liposomes, Biochim. Biophys. Acta 1148 (1993) 77-84.
10. A.K. Kenworthy, S.A. Simon, T.J. McIntosh, Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol), Biophys. J. 68(5) (1995) 1903-1920.
11. F.K. Bedu-Addo, P. Tang, Y. Xu, L. Huang, Effects of polyethylene glycol chain length and phsopholipid acyl chain composition on the interaction of polyethylene glycolphsopholipid conjugates with phospholipid: implications in liposomal drug delivery, Pharm. Res. 13(5) (1996) 710-717.
12. T. Yuda, K. Maruyyama, M. Iwatsuru, Prolongation of liposome circulation time by various derivatives of polyethylene glycols, Biol. Pharm.Bull. 19(10) (1996) 1347-1351.
13. J.M. Van Alstine, M. Malmsten, D.E. Brooks, Poly(ethylene glycol) amphiphile adsorption and liposome partition, J. Chromatogr. B. Biomed. Appl. 680(1-2) (1996) 145-155.
14. R. Zeisig, K. Shimada, S. Hirota, D. Ardnt, Effect of sterical stabilization on macrophage uptake in vitro and on thickness oof the fixed aqueous layer of liposomes made from alkylphosphocholines, Biochim. Biophys. Acta 1285(2) (1996) 237-245.
15. G. Basanez, F.M. Goni, A. Alonso, Poly(ethylene glycol)-lipid conjugates inhibit phospholipase C-induced lipid hydrolysis, liposome aggregation and fusion through independent mechanisms, FEBS Lett. 411(2-3) (1997) 281-286.
16. D. Needham, N. Stoicheva, D. Zhelev, Exchange of monooleoylphosphatidylcholine as monomer and micelle with membranes containing poly(ethylene glycol)-lipid, Biophys. J. 73(5) (1997) 2615-2629.
17. K. Moribe, K. Maruyama, M. Iwatsuru, Estimation of surface state of poly(ethylene glycol)-coated liposomes using an aqueous two-phase partitioning technique, Chem. Pharm. Bull. 45(10) (1997) 1683-1687.
18. O. Tirosh, Y. Barenholz, J. Katzhendler, A. Priev, Hydration of polyethylene glycol-grafted liposomes, Biophys. J. 74(3) (1998) 1371-1379.
19. V.P. Torchilin, V.S. Trubetskoy, K.R. Whiteman, P. Caliceti, P. Ferruti, F.M. Veronese, New synthetic amphiphilic polymers for steric protection of liposomes in vivo J, Pharm. Sci. 884(9) (1995) 1049-1053.
20. A.L. Klibanov, K. Maruyama, A.M. Beckerleg, V.P. Torchilin, L. Huang, Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target, Biochim. Biophys. Acta 1062(2) (1991) 142-148.
21. S. Shahinian, J.R. Silvius, A novel strategy affords high-yield coupling of antibody Fab′ fragments to liposomes, Biochim. Biophys. Acta 1239(2) (1995) 157-167.
22. C.B. Hansen, G.Y. Kao, E.H. Moase, S. Zalipsky, T.M. Allen, Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures, Biochim. Biophys. Acta 1239(2) (1995) 133-144.
23. S. Suzuki, S. Watanabe, T. Masuko, Y. Hashimoto, Preparation of long-circulating immunoliposomes containing adriamycin by a novel mehtod to coat immunoliposomes with poly(ethylene glycol), Biochim. Biophys. Acta 1245(1) (1995) 9-16.
24. T.M. Allen, E. Brandeis, C.B. Hansen, G.Y. Kao, S. Zalipsky, A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells, Biochim. Biophys. Acta 1237(2) (1995) 99-108.
25. S. Zalipsky, N. Mullah, J.A. Harding, J. Gittelman, L. Guo, S.A. deFrees, Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains, Bioconjugate Chem. 8(2) (1997) 111-118.
26. J. Huwyler, D. Wu, W.M. Pardridge, Brain drug delivery of small molecules using immunoliposomes, Proc. Natl. Acad. Sci. USA 93(24) (1996) 14164-14169.
27. D. Kirpotin, J.W. Park, K. Hong, S. Zalipsky, W.L. Li, P. Carter, C.C. Benz, D. Papahadjopoulos, Sterically stabilized anti-HERS immunoliposomes: design and targetting to human breast cancer cells in vitro, Biochemistry 36(1) (1997) 66-75.
28. K. Maruyama, N. Takahashi, T. Tagawa, K. Ngaike, M. Iwatsuru, Immunoliposomes bearing polyethylene glycol-coated Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo, FEBS Lett. 413(1) (1997) 177-180.
29. D. Arndt, R. Zeisig, I. Eue, B. Sternberg, I. Fuchtner, Antineoplastic activity of sterically stabilized alkylphsophocholine liposomes in humna breast carcinomas, Breast Cancer Res. Treat. 43(3) (1997) 237-246.
30. K. Shimada, J.A. Kamps, J. Regts, K. Ikeda, T. Shiozawa, S. Hirota, G.L. Scherphof, Biodistribution of liposomes containing synthetic galactose-terminated diacylglyceryl-poly-(ethylene glycol)s, Biochim. Biophys. Acta 1326(2) (1997) 329-341.
31. J.A. Harding, C.M. Engbers, M.S. Newman, N.I. Goldstein, S. Zalipsky, Immunogenicity and pharmacokinetic attributes of poly(ethylenen glycol)-grafted immunoliposomes, Biochim. Biophys. Acta 1327(2) (1997) 181-192.
32. P. Deol, G.K. Khuller, Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice, Biochim. Biophys. Acta 1334(2-3) (1997) 161-172.
33. V.S. Trubetskoy, J.A. Cannillo, A. Milshtein, G.L. Wolf, V.P. Torchilin, Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties, Magn. Reson. Imag. 13(1) (1995) 31-37.
34. V.P. Torchilin, J. Narula, E. Halpern, B.A. Khaw, Poly-(ethylene glycol)-coated anti-cardiac myosin immunoliposomes:factors influencing target accumulation in the infarcted myocardium, Biochim. Biophys. Acta 1279(1) (1996) 75-83.
35. K.C. Li, L.R. Pelc, S.A. Napel, M.L. Goris, D.T. Lin, C.K. Song, A.N. Leung, G.D. Rubin, M.D. Hollett, D.P. Harris, MRI of pulmonary embolism using Gd-DTPA-polyethylene glycol polymer enhanced 3D fast gradient echo technique in a canine model, Magn. Reson. Imag. 15(5) (1997) 543-550.
36. K. Adzamli, R.B. Dorshow, M.R. Hynes, D.L. Nosco, M.D. Adams, Characterization of polyethylene glycol-stabilized, manganese-substitutedhydroxylapatite (MnHA-PEG). A potential MR blood pool agent, Acta Radiol. Suppl. 412 (1997) 73-78.
37. A. Sachse, J.U. Leike, T. Schneider, S.E. Wagner, G.L. Rossling, W. Krause, M. Brandl, Biodistribution and computed tomography blood-pool imaging properties of polyethylene glycol-coated iopromide carrying liposomes, Invest. Radiol. 32(1) (1997) 44-50.
38. C. Oussoren, G. Storm, Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethylene glycol), Pharm. Res. 14(10) (1997) 1479-1484.
39. W. Grunder, M. Biesold, M. Wagner, A. Werner, Improved nuclear magnetic resonance microscopic visualization of joint cartilage using liposome entrapped contrast agents, Invest. Radiol. 33(4) (1998) 193-202.
40. O.C. Boerman, W.J. Oyen, L. van Bloois, E.B. Koenders, J.W. van der Meer, F.H. Corstens, G. Storm, Optimization of technetium-99m labeled PEG liposomes to image focal infection: effects of particle size and circulation time, J. Nucl. Med. 38(3) (1997) 489-493.
41. B. Goins, W.T. Phillips, R. Klipper, Blood pool imaging using technetium-99m-labeled liposomes, J. Nucl. Med. 37(8) (1996) 1374-1379.
42. N. Oku, Y. Tokudome, H. Tsuukada, T. Kosugo, Y. Namba, S. Okada, In vivo trafficking of long-circulating liposomes in tumor-bearing mice determined by positron emission tomography, Biopharm. Drug Dispos. 17(5) (1996) 435-441.
43. S.M. Demos, H. Onyuksel, J. Gilbert, S.I. Roth, B. Kane, P. Jungblut, J.V. Pinto, D.D. McPherson, M.E. Klegerman, In vitro targeting of antibody-conjugated echogenic liposomes for site-specific ultrasonic image enhancement, J. Pharm. Sci. 86(2) (1997) 167-171.
44. E.C. Unger, T.P. McCreery, R.H. Sweitzer, D. Shen, G. Wu, In vitro studies of a new thrombus-specific ultrasound contrast agent, Am. J. Cardiol. 81(12A) (1998) 58G-61G.
45. N.A. Matwioff, Magnetic Resonance Workbook. Raven Press, New York, 1989.
46. A.L. Horowitz, MRI Physics for Radiologists. A Visual Approach, 2nd ed. Springer, New York, 1991.
47. D.D. Stark, W.G. Bradley, Magnetic Resonance Imaging. Mosby, St. Louis, 1988.
48. I. Bertini, C. Luchinat, NMR of Paramagnetic Molecules in Biological Systems. Benjamin Cummings, Menlo Park, CA, 1986.
49. S.H. Koenig, From the relaxation of Gd-DTPA to everything else, Magn. Reson. Med. 22 (1991) 183-190.
50. K.J. Packer, The effects of diffusion through locally inhomogeneous magnetic fields on transverse nucelar spin relaxation in heterogenous systems. Proton transverse relaxation in striated muscle, J. Magn. Reson. 9 (1973) 438.
51. P. Gillis, S.H. Koenig, Trasnverse relaxation of solvent protons indiced by magnetized spheres: application to ferritin, eryhtrocytes and magnetite, Magn. Reson. Med. 5 (1987) 323-345.
52. R.N. Muller, P. Gillis, F. Moiny, A. Roch, Transverse relaxivity of particulate MRI contrast media:from theories to experiments, Magn. Reson. Med. 22 (1991) 178-182.
53. C. Tilcock, Q.F. Ahkong, S.H. Koenig, R.D. Brown, M. Davis, G. Kabalka, The design of liposomal paramagnetic MR agents: effect of vesicle size upon the relaxivity of surface-incorporated lipophilic chelates, Mag. Reson. Med. 27 (1992) 44-52.
54. D. Barsky, B. Putz, K. Schulten, Theory of heterogeneous relaxation in compartmentalized tissues, Magn. Reson. Med. 37(5) (1997) 666-675.
55. C. Axmann, K. Bohndorf, J. Gellissen, A. Prescher, M.R. Lodemann, A comparison between GE and SE sequences in MRT after the i.v. application of superparamagnetic iron particles in the assessment of experimentally induced soft-tissue osteosarcomas, Fortschr. Geb. Rontgenstr. Neuen. Bildgeb. Verfahr. 166(2) (1997) 146-152.
56. V. Rousseau, B. Denizot, D. Pouliquen, P. Jallet, J.J. Le Jeune, Investigation of blood-brain barrier permeability to magnetite-dextran nanoparticles (MD3) after osmotic disruption in rats, Magma 5(3) (1997) 213-222.
57. M. Saeed, M.F. Wendland, M. Engelbrecht, H. Sakuma, C.B. Higgins, Value of blood pool contrast agents in magnetic resonance angiography of the pelvis and lower extremities, Eur. Radiol. 8(6) (1998) 1047-1053.
58. A.L. Alexander, T.T. McCreery, T.R. Barrette, A.F. Gmitro, E.C. Unger, Microbubbles as novel pressure-sensitive MR contrast agents, Magn. Reson. Med. 35(6) (1996) 801-806.
59. D. Barsky, B. Putz, K. Schulten, R.L. Magin, Theory of paramagnetic contrast agents in liposome systems, Mag. Reson. Med. 24 (1992) 1-17.
60. S.H. Koenig, Q.F. Ahkong, R.D. Brown, M. Lafleur, M. Spiller, E. Unger, C. Tilcock, Permeability of liposomal membranes to water - results from the magnetic field dependence of solvent protons in suspensions of vesicles with entrapped paramegnetic ions, Mag. Reson. Med. 23 (1992) 275.
61. G.W. Kabalka, E. Buonocore, K. Hubner, M. Davis, L. Huang, Gadolinium-labeled liposomes:targeted MR contrast agents for the liver and spleen, Radiology 163 (1987) 255.
62. G. Kabalka, E. Buonocore, K. Hubner, M. Davis, L. Huang, Gadolinium-labeled liposomes containing paramagnetic amphipathic agents: targeted MRI contrast agents for the liver, Magn. Reson. Med. 8 (1989) 89.
63. C. Grant, S. Karlik, E. Florio, A liposomal MRI contrast agent:phosphatidylethanolamine-DTPA, Magn. Reson. Med. 11 (1989) 236.
64. R. Schwendener, R. Wuthrich, S. Duewell, G. Westera, G.K. von Schultess, A pharmacokinetic and MRI study of unilamellar gadolinium- manganese and iron-DTPA-stearate liposomes as organ-specific contrast agents, Invest. Radiol. 25 (1990) 992.
65. R. Schwendener, Liposomes as carriers for paramagnetic gadolinium chelates as organ specific contrast agents for magnetic resonance imaging, J. Liposome Res. 4(2) (1994) 837-855.
66. V.S. Trubetskoy, V.P. Torchilin, New approches in the chemical design of Gd-containing liposomes in magnetic resonance imaging of lymph nodes, J. Liposome Res. 4(2) (1994) 961-980.
67. B. Misselwitz, S. Sachse, A Interstitial MR lymphography using Gd-carrying liposomes, Acta Radiol Suppl. 412 (1997) 51-55.
68. E.R. Wisner, K.L. Aho-Sharon, M.J. Bennett, S.G. Penn, C.B. Lebrilla, M.H. Nantz, A modular lymphographic magnetic resonance imaging contrast agent:contrast enhancement with DNA transfection potential, J. Med. Chem. 40(25) (1997) 3992-3996.
69. P. Leander, S. Mansson, T. Ege, J. Besjakov, CT and MR imaging of the liver using liver-specific contrast media. A comparative study in a tumour model, Acta Radiol. 37(3) (1996) 242-249.
70. M.D. Bednarski, J.W. Lee, M.R. Callstrom, K.C. Li, In vivo target-specific delivery of macromolecular agents with MR-guided focused ultrasound, Radiology 204(1) (1997) 263-268.
71. S. Pauser, R. Reszka, S. Wagner, K.J. Wolf, H.J. Buhr, G. Berger, Liposome-encapsulated superparamagnetic iron oxide particles asmarkers in an MRI-guided search for tumor-specific drug carriers, Anticancer Drug Des. 12(2) (1997) 125-135.
72. S.E. Seltzer, Contrast carrying liposomes: current status, Invest. Radiol. 23 (1988) S122-S125.
73. C. Tilcock, D. Utkhede, G. Meng, Vesicles as imaging agents, in: M. Rosoff (Ed.), Vesicles: Surfactant Science Series, vol. 62, 1996, pp. 593-648.
74. X. Fouillet, H. Tournier, H. Khan, S. Sabitha, S. Burkhardt, F. Terrier, M. Schneider, Enhancement of computed tomography liver contrast using iomeprol-containing liposomes and detection of small liver tumors in rats, Acad. Radiol. 2(7) (1995) 576-583.
75. U.P. Schmiedl, W. Krause, J. Leike, J.A. Nelson, G. Schuhmann-Giampieri, Liver contrast enhancement in primates using iopromide liposomes, Acad. Radiol. 2(11) (1995) 967-972.
76. W. Krause, J. Leike, G. Schuhmann-Giampieri, A. Sachse, U. Schmiedl, H. Strunk, Iopromide-carrying liposomes as a contrast agent for the liver, Acad. Radiol. Suppl. 2 (1996) S235-S237.
77. P. Leander, A new liposomal contrast medium for CT of the liver. An imaging study in a rabbit tumour model, Acta Radiol. 37(1) (1996) 63-68.
78. A. Dick, G. Adam, J. Tacke, A. Prescher, T.E. Southon, R.W. Gunther, Computed tomography of experimental liver abscesses using a new liposomal contrast agent, Invest. Radiol. 31(4) (1996) 194-203.
79. P. Hoglund, P. Leander, S.O. Hustvedt, Y. Kloster, A. Borseth, Human pharmacokinetics and modeling of the concentration-attenuationrelationship of a new liposomal liver-specific contrast agent for CT, Acad Radiol. 5(Suppl. 1) (1998) S47-S48.
80. P. Leander, P. Hoglund, Y. Kloster, A. Borseth, A new liposomal liver-specific contrast agent for CT: first human phase I clinical trial assessing efficacy and safety, Acad Radiol. 5(Suppl. 1) (1998) S6-S8.
81. C. Tilcock, Q.F. Ahkong, D. Fisher, 99mTc-labeling of lipid vesicles containing the lipophilic chelator PE-DTTA: effect of tin-to-chelate ratio, chelate content and surface polymer on labeling efficiency and biodistribution behavior, Nucl. Med. Biol. 21 (1994) 89-96.
82. C. Tilcock, M. Yap, M. Szucs, D. Utkhede, PEG-modified lipid vesicles with encapsulated technetium-99m as blood pool agents for nuclear medicine, J. Nucl. Med. 21 (1994) 165-170.
83. D. Utkhede, C. Tilcock, Effect of lipid dose on the biodistribution and blood pool clearance kinetics of PEG-modified technetium-labeled vesicles, J. Liposome Res. 8(3) (1998) 381-390.
84. A. Khalifa, D. Dodds, R. Rampling, J. Paterson, T. Murray, Liposomal distribution in malignant glioma: possibilities for therapy, Nucl. Med. Commun. 18(1) (1997) 17-23.
85. M.C. Woodle, 67-Gallium-labeled liposomes with prolonged circulation: preparation and potential as nucelar imaging agents, Nucl. Med. Biol. 20(2) (1993) 149-155.
86. W.T. Phillips, A.S. Rudolph, B. Goins, J.H. Timmons, R. Klipper, R. Blumhardt, A simple method for producing a technetium-99m labeled liposome which is stable in vivo, J. Nucl. Med. 19 (1992) 539-547.
87. D. Utkhede, C. Tilcock, 1998 (unpublished results).
88. R. Goto, Tissue distribution of 99mTc-labeled liposomes prepared from synthetic amphiphiles containing amino acid reidues, J. Liposome Res. 4(2) (1994) 877-905.
89. D.S. Alberts, D.J. Garcia, Safety aspects of pegylated liposomal doxorubicin in patients with cancer, Drugs 54 (1997) 30-35.
90. P.K. Working, A.D. Dayan, Pharmacological/toxicological expert report. Caelyx™ (Stealth Liposomal Doxorubicin HCl), Hum. Exp. Toxicol. 15(9) (1996) 752-785.
91. W.J. Oyen, O.C. Boerman, E.T. Dams, G. Storm, L. van Bloois, E.B. Koenders, U.J. van Haelst, J.W van der Meer, F.H. Corstens, Scinitgraphic evaluation of experimental colitis in rabbits, J. Nuc. Med. 38(10) (1997) 1596-1600.
92. O.C. Boerman, W.J. Oyen, G. Storm, M.L. Corvo, L. van Bloois, J.W. van der Meer, F.H. Corstens, Technetium-99m labeled liposomes to image experimental arthritis, Ann. Rheum. Dis. 56(6) (1997) 369-373.
93. C. Oussoren, G. Storm, Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. III. Influence of surface modification with poly(ethylene glycol), Pharm. Res. 14(10) (1997) 1479-1484.
94. D. Andreopoulos, L.P. Kasi, 99mTc-labeled diphytanoylphosphatidylcholine liposomes: in vitro and in vivo studies, J. Microencapsul. 14(4) (1997) 427-436.
95. R. Schurmann, R. Schlief, Saccharide-based contrast agents. Characteristics and diagnostic potential, Radiol. Med. (Torino) 87(5) (1994) 15-23.
96. R. Schlief, Developments in echo-enhancing agents, Clin. Radiol. 51(1) (1996) 5-7.
97. M.L. Melany, E.G. Grant, Clinical experience with sonographic contrast agents, Semin. Ultrasound CT MR 18(1) (1997) 3-12.
98. J. Holte, C. Rasmussen, H. Morris, First clinical experience with sonicated human serum albumin (Albunex) as an intrafallopian ultrasound contrast medium, Ultrasound Obstet. Gynecol. 6(1) (1995) 62-65.
99. B. Geny, P. Bischoff, B. Muan, F. Piquard, J.C. Thiranos, E. Epailly, M. Lambrechs, A. Juelsrud-Vebner, B. Eisenmann, P. Haberey, Safety of a new transpulmonary echocontrast agent (Albunex) in repeated echocardiographic studies in patients, Clin. Cardiol. 20(2) (1997) 111-115.
100. M.S. Dolan, J. Dent, C. deFilippi, T. Christopher, J.H. Wible Jr., A.J. Labovitz, Increasing the dose and rate of Albunex infusion leads to superior left ventricular contrast effect, J. Am. Soc. Echocardiogr. 11(5) (1998) 426-432.
101. N. Ono, H. Ijuin, N. Ono, Y. Tateishi, R. Ogata, R. Kuromatsu, S. Itano, M. Sata, K. Tanikawa, The diagnosis of the early stage of hepatocellular carcinoma by US-angiography with intraarterial Albunex (sonicated serum albumin) infusion, Nippon Rinsho 56(4) (1998) 956-960.
102. K. Holz, R. Becker, R. Schurmann, Ultrasound in the investigation of tubal patency. A meta-analysis of threecomparative studies of Echovist-200 including 1007 women, Zentralbl. Gynakol. 119(8) (1997) 366-373.
103. D.M. Skyba, G. Camarano, N.C. Goodman, R.J. Price, T.C. Skalak, S. Kaul, Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second-generation echocardiographic contrastagent capable of producing myocardial opacification from a venous injection, J. Am. Coll. Cardiol. 28(5) (1996) 1292-1300.
104. P.D. Krishna, V.L. Newhouse, Second harmonic characteristics of the ultrasound contrast agents albunex and FSO69, Ultrasound Med. Biol. 23(3) (1997) 453-459.
105. T.R. Porter, F. Xie, K. Kilzer, Intravenous perfluoropropane-exposed sonicated dextrose albumin produces myocardial ultrasound contrast that correlates with coronary blood flow, J. Am. Soc. Echocardiogr. 8(5) (1995) 710-718.
106. S.C. Quay, A.J. Eisenfeld, Safety assessment of the use of perflenapent emulsion for contrast enhancement of echocardiography and diagnostic radiology ultrasound studies, Clin. Cardiol. 20(10 Suppl 1) (1997) I19-I26.
107. D.L. Miller, R.A. Gies, Enhancement of ultrasonically-induced hemolysis by perfluorocarbon-based compared to air-based echo-contrast agents, Ultrasound Med. Biol. 24(2) (1998) 285-292.
108. E. Unger, D. Shen, T. Fritz, B. Kulik, P. Lund, G.L. Wu, D. Yellowhair, R. Ramaswami, T. Matsunaga, Gas-filled lipid bilayers as ultrasound contrast agents, Invest. Radiol. 29(Suppl. 2) (1994) S134-S136.
109. E. Barbarese, S.Y. Ho, J.S. D'Arrigo, R.H. Simon, Internalization of microbubbles by tumor cells in vivo and in vitro, J. Neuro-oncol. 26(1) (1995) 25-34.
110. H. Alkan-Onyuksel, S.M. Demos, G.M. Lanza, M.J. Vonesh, M.E. Klegerman, B.J. Kane, J. Kuszak, D.D. McPherson, Development of inherently echogenic liposomes as an ultrasonic contrastagent, J. Pharm. Sci. 85(5) (1996) 486-490.
111. P.J. Frinking, N. de Jong, Acoustic modeling of shell-encapsulated gas bubbles, Ultrasound Med. Biol. 24(4) (1998) 523-533.
112. J.R. Lindner, J.M. Dent, S.P. Moos, A.R. Jayaweera, S. Kaul, Enhancement of left ventricular cavity opacification by harmonic imaging after venous injection of Albunex, Am. J. Cardiol. 79(12) (1997) 1657-1662.
113. M. Hasegawa, Y. Saiki, H. Kayano, T. Katagiri, Assessment of myocardial perfusion with second harmonic imaging using intravenous injection of Albunex and Levovist, Nippon Rinsho 56(4) (1998) 903-908.
114. C. Firschke, J.R. Lindner, N.C. Goodman, D.M. Skyba, K. Wei, S. Kaul, Myocardial contrast echocardiography in acute myocardial infarction using aortic root injections of microbubbles in conjunction with harmonic imaging: potential application in the cardiac catheterization laboratory, J. Am. Coll. Cardiol. 29(1) (1997) 207-216.
115. D.L. Miller, S.J. Bao, The relationship of scattered subharmonic, 3.3-MHz fundamental and second harmonic signals to damage of monolayer cells by ultrasonically activated Albunex, Acoust. Soc. Am. 103(2) (1998) 1183-1189.
116. Y. Hirooka, H. Goto, A. Ito, S. Hayakawa, Y. Watanabe, Y. Ishiguro, S. Kojima, T. Hayakawa, Y. Naitoh, Contrast-enhanced endoscopie ultrasonography in pancreatic diseases: a preliminary study, Am. J. Gastroenterol. 93(4) (1998) 632-635.
117. A.A. Brayman, M. Azadniv, M.W. Miller, R.S. Meltzer, Effect of static pressure on acoustic transmittance of Albunex microbubble suspensions, J. Acoust. Soc. Am. 99(4 Pt 1) (1996) 2403-2408.
118. S. Tiukinhoy, S. Bhoopalam, J.W. Winkelmann, K. Ammar, L. Mangulabnan, G. Reddy, A. Fernandez, R. Block, V. Malhotra, S. Feinstein, Loss of contrast intensity during systole in the left ventricular cavity with the use of the contrast agent Albunex. An analysis of its correlation with pressure and velocity, Invest. Radiol. 31(7) (1996) 415-422.
119. J. Wu, Temperature rise generated by ultrasound in the presence of contrast agent, Ultrasound Med. Biol. 24(2) (1998) 267-274.
120. A.A. Brayman, P.L. Strickler, H. Luan, S.L. Barned, C.H. Raeman, C. Cox, M.W. Miller, Hemolysis of 40% hematocrit, Albunex-supplemented humanerythrocytes by pulsed ultrasound: frequency, acoustic pressure andpulse length dependence, Ultrasound Med. Biol. 23(8) (1997) 1237-1250.
121. D. Dalecki, C.H. Raeman, S.Z. Child, D.P. Penney, E.L. Carstensen, Remnants of Albunex nucleate acoustic cavitation, Ultrasound Med. Biol. 23(9) (1997) 1405-1412.